PET/CT Imaging in Gynecologic Malignancies Other than Ovarian and Cervical Cancer

Priya Bhosale; Revathy Iyer; Anuja Jhingran; Donald Podoloff

doi:10.1016/j.cpet.2010.07.005

PET/CT Imaging in Gynecologic Malignancies Other than Ovarian and Cervical Cancer

PET Clin. 2010 Oct;5(4):463-75. doi: 10.1016/j.cpet.2010.07.005. Epub 2010 Aug 11.

Authors

Priya Bhosale¹, Revathy Iyer², Anuja Jhingran³, Donald Podoloff⁴

Affiliations

¹ Department of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA. Electronic address: Priya.bhosale@mdanderson.org.
² Department of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA.
³ Department of Radiation Oncology Treatment, University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA.
⁴ Department of Nuclear Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA.

PMID: 27157973
DOI: 10.1016/j.cpet.2010.07.005

Abstract

Fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) is an imaging modality used for staging, assessing response to therapy, and diagnosis of recurrent cervical and ovarian cancer. The potential role of FDG-PET/CT in other gynecologic malignancies such as endometrial cancer, uterine sarcomas, vaginal, and vulvar cancer has not been fully explored.

Keywords: Endometrial cancer; PET; Uterine cancer; Vaginal cancer; Vulvar cancer.

Published by Elsevier Inc.

Publication types

Review